Rare metachronous advanced colorectal cancer coexisting with lymphoma: a case report with over 10-year survival
- 1Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Abstract
Background: Multiple primary malignancies (MPMs) are increasingly encountered in clinical practice as cancer survivorship improves. The coexistence of colorectal cancer (CRC) and lymphoma is rare, and long-term survival exceeding 10 years in such patients has seldom been reported.
Case presentation: We report a 63-year-old male patient who presented with sigmoid colon adenocarcinoma with synchronous multiple liver metastases (cT4N1M1, Stage IV) in 2015. Molecular testing of the primary sigmoid colon tumor specimen revealed wild-type KRAS, NRAS, BRAF, and PIK3CA.After multidisciplinary team (MDT) discussion, the patient received 4 cycles of FOLFIRI regimen chemotherapy as conversion therapy, achieving partial response (PR). He subsequently underwent special hepatic segmentectomy and laparoscopic-assisted radical sigmoidectomy, followed by additional chemotherapy. Evaluation in May 2016 showed complete response (CR) with no evidence of disease (NED). During regular follow-up in 2021, a left inguinal lymph node enlargement was detected. Biopsy confirmed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), CD30-positive. The patient received 6 cycles of CHOP chemotherapy combined with local radiotherapy, achieving CR. In March 2026, retroperitoneal lymph node recurrence was confirmed, and continued chemotherapy was recommended. The patient has achieved an overall survival of over 10 years since the initial CRC diagnosis.
Conclusion: This case suggests that, with MDT-guided individualized treatment, long-term survival may be achievable in patients with advanced CRC and liver metastases following conversion therapy and radical surgery. The subsequent development of a second primary PTCL-NOS highlights the importance of vigilant long-term surveillance in cancer survivors. This report adds to the limited literature on MPMs involving CRC and lymphoma with extended survival.
Related
- Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial
- Understanding PD-1 Inhibitors in Hodgkin Lymphoma: A Guide for the Oncology Advanced Practitioner
- Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real‐World Analysis From REALYSA, a LYSA Cohort
- Association between primary-site surgery and overall survival in non-metastatic and metastatic colorectal cancer: a population-based study using the Surveillance, Epidemiology, and End Results database
- A clinicopathological and hematological biomarker-based nomogram for overall survival in early-onset colorectal cancer: development, external validation, and translational implications
BibTeX
@article{ma2026rare,
title = {{Rare metachronous advanced colorectal cancer coexisting with lymphoma: a case report with over 10-year survival}},
author = {Yue Ma and Ting Han and Xiaolin Lin and Xiuying Xiao},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1952530},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1952530/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rare metachronous advanced colorectal cancer coexisting with lymphoma: a case report with over 10-year survival
AU - Yue Ma
AU - Ting Han
AU - Xiaolin Lin
AU - Xiuying Xiao
PY - 2026
DA - 2026/10/21
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1952530
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1952530/full
AB - Background: Multiple primary malignancies (MPMs) are increasingly encountered in clinical practice as cancer survivorship improves. The coexistence of colorectal cancer (CRC) and lymphoma is rare, and long-term survival exceeding 10 years in such patients has seldom been reported. Case presentation: We report a 63-year-old male patient who presented with sigmoid colon adenocarcinoma with synchronous multiple liver metastases (cT4N1M1, Stage IV) in 2015. Molecular testing of the primary sigmoid colon tumor specimen revealed wild-type KRAS, NRAS, BRAF, and PIK3CA.After multidisciplinary team (MDT) discussion, the patient received 4 cycles of FOLFIRI regimen chemotherapy as conversion therapy, achieving partial response (PR). He subsequently underwent special hepatic segmentectomy and laparoscopic-assisted radical sigmoidectomy, followed by additional chemotherapy. Evaluation in May 2016 showed complete response (CR) with no evidence of disease (NED). During regular follow-up in 2021, a left inguinal lymph node enlargement was detected. Biopsy confirmed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), CD30-positive. The patient received 6 cycles of CHOP chemotherapy combined with local radiotherapy, achieving CR. In March 2026, retroperitoneal lymph node recurrence was confirmed, and continued chemotherapy was recommended. The patient has achieved an overall survival of over 10 years since the initial CRC diagnosis. Conclusion: This case suggests that, with MDT-guided individualized treatment, long-term survival may be achievable in patients with advanced CRC and liver metastases following conversion therapy and radical surgery. The subsequent development of a second primary PTCL-NOS highlights the importance of vigilant long-term surveillance in cancer survivors. This report adds to the limited literature on MPMs involving CRC and lymphoma with extended survival.
SN - 2234-943X
ER -